Effect of surgical treatment for N2-positive c-stage III non-small cell lung carcinoma in the “PACIFIC” era

• Published in: Clinical lung cancer 2023-12, Vol.24 (8), p.733-742
• Main Authors: Adachi, Hiroyuki, Ito, Hiroyuki, Isaka, Tetsuya, Murakami, Kotaro, Miura, Jun, Kikunishi, Noritake, Shigeta, Naoko, Saito, Haruhiro, Yoshida, Daisaku, Yokose, Tomoyuki, Saito, Aya
• Format: Article
• Language: English
• Subjects: Carcinoma, Non-Small-Cell Lung - pathology; Chemoradiotherapy; durvalumab; Humans; locally advanced; Lung Neoplasms - pathology; lymph node metastasis; Neoplasm Staging; Non-small cell lung cancer; Proportional Hazards Models; Treatment Outcome
• ISSN: 1525-7304; 1938-0690
• DOI: 10.1016/j.cllc.2023.07.004

The PACIFIC trial findings drastically changed the c-stage III non-small cell lung cancer (NSCLC) treatment strategy. However, it remains uncertain whether surgery is no longer needed for treatment. We aimed to evaluate the efficacy of surgery and explore the prognostic factors of better outcomes in surgery-treated patients than in PACIFIC regimen-treated patients. From 2010 to 2020, 107 patients with clinical N2-stage III NSCLC underwent lung resection in our institute. We analyzed and compared the yearly postoperative overall survival (OS) benchmarks of these patients to those of patients treated in the PACIFIC trial. The 1-, 2-, 3-, 4-, and 5-year OS rates of patients were 87.7%, 73.9%, 64.9%, 58.2%, and 55.4%, respectively, all of which were superior to those of PACIFIC regimen-treated patients. However, patients with cT3/T4 tumors and skip, multi-station, distant, and bulky N2 metastases, as well as those who underwent bronchoplasty, showed inferior results in several yearly benchmarks than in PACIFIC regimen-treated patients. Multivariate analyses conducted among factors mentioned above showed that cT3/T4 tumor was a worse prognostic factor for surgery-treated patients than for PACIFIC regimen-treated patients (hazard ratio [HR] 1.89, p = 0.036). Distant N2 metastasis was also a worse prognostic factor, although its effect was not statistically significant (HR 1.81, p = 0.082). Surgery remains the mainstay of N2-positive c-stage III NSCLC treatment, and the PACIFIC regimen may be suitable only for patients with unresectable disease. However, surgery should be cautiously considered for patients with cT3/4 disease. To explore preoperative factors indicating better outcomes for surgery-treated than PACIFIC regimen-treated (control arm) patients with cN2-stage III non-small cell lung cancer (NSCLC), we analyzed postoperative 107 patients with cN2-stage III NSCLC. Postoperative overall survival was generally better than that reported by the PACIFIC trial. However, patients with cT3/4 tumors may be eligible for chemoradiotherapy followed by durvalumab administration.